Sanofi & GSK to support COVAX with 200 m adjuvanted recombinant protein-based COVID-19 vaccines
Sanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read more
DISEASES
Lilly to supply 300,000 vials of COVID-19 monoclonal antibody to the U.S.
Eli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read more
Janssen applies to FDA for New Indication of XARELTO® for Peripheral Artery Disease
The Janssen Pharmaceutical Companies of Johnson & Johnson revealed on Monday the submission of the supplemental New Drug Application (sNDA)
Read more
Moderna signs agreement to supply Qatar with mRNA COVID-19 vaccine
American biotech Moderna has signed an agreement with the Ministry of Public Health to supply Qatar with its mRNA COVID-19
Read more
AstraZeneca receives FDA authorisation to resume COVID-19 vaccine trial
AstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read more
Phenomic AI starts with $6M using AI/ML for Targeting the Tumor Stroma
Phenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read more
FDA approves Roche’s Venclexta combos for acute myeloid leukaemia
Roche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read more
SYNLAB validates saliva sampling method for SARS-CoV-2 testing
SYNLAB, leading European provider of medical diagnostic solutions, has revealed the successful authorization of saliva sampling platform, another groundbreaking non-invasive
Read more
The Acceleration of Digitalisation in Pharma in 2020
This year, more than ever has required the pharma industry to dive into digitalisation in all shapes and forms. With
Read more
Lilly’s Mirikizumab shows reduction of Intestinal Inflammation in Crohn’s Disease
Eli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read more